Physician profile
Jay E Sidloski
NPI 1912950502
$14,750.45
in general payments reported to CMS, 2019-2025
82 companies · $3,078 in 2025
The $3,078 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,984 · 2020: $263 · 2021: $25.78 · 2022: $512 · 2023: $6,470 · 2024: $2,419 · 2025: $3,078.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,314 · Consulting Fee: $4,000 · Travel and Lodging: $444 · Education: $209.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,314.05 |
| Consulting Fee | $4,000.00 |
| Travel and Lodging | $443.88 |
| Education | $209.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $4,443.88 | 2023 | |
| E.R. Squibb & Sons, L.L.C. | $633.12 | 2019-2025 | Opdivo, Opdualag, Eliquis |
| Pfizer INC. | $611.73 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $588.94 | 2019-2025 | |
| Abbvie INC. | $512.35 | 2019-2025 | Venclexta |
| Astrazeneca Pharmaceuticals Lp | $487.52 | 2019-2025 | Imfinzi, Calquence, Enhertu |
| Regeneron Healthcare Solutions, INC. | $356.72 | 2019-2025 | Libtayo, Lynozyfic |
| Janssen Biotech, INC. | $351.92 | 2019-2025 | Tecvayli, Rybrevant, Talvey |
| Takeda Pharmaceuticals U.S.A., INC. | $344.97 | 2019-2025 | Fruzaqla, Ninlaro, Alunbrig |
| Lilly USA, LLC | $285.51 | 2019-2025 | Jaypirca, Verzenio, Retevmo |
| Eisai INC. | $279.98 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $276.78 | 2019-2025 | Keytruda, Lynparza, Reblozyl |
| Sirtex Medical INC | $268.38 | 2023-2024 | Sir-Spheres Microspheres |
| Celgene Corporation | $256.57 | 2019-2025 | Reblozyl, Pomalyst |
| Asd Specialty Healthcare, LLC | $247.90 | 2019 |
Show all 82 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $235.13 | 2019-2025 | |
| Myriad Genetic Laboratories, INC. | $227.01 | 2023-2025 | Myrisk |
| Genentech USA, INC. | $211.33 | 2022-2025 | Phesgo, Tecentriq, Itovebi |
| Astellas Pharma US INC | $208.83 | 2019-2025 | Padcev, Vyloy, Xtandi |
| Genzyme Corporation | $207.72 | 2019-2025 | |
| Exelixis INC. | $207.40 | 2019-2025 | Cabometyx |
| Seagen INC. | $188.51 | 2019-2025 | |
| Incyte Corporation | $185.40 | 2020-2025 | Jakafi, Monjuvi, Niktimvo |
| Emd Serono, INC. | $184.64 | 2019-2025 | Bavencio |
| Amgen INC. | $166.73 | 2019-2020 | |
| Daiichi Sankyo INC. | $136.26 | 2024-2025 | Enhertu, Datroway |
| Karyopharm Therapeutics INC. | $128.44 | 2020-2024 | Xpovio |
| Genmab U.S., INC. | $111.29 | 2023-2025 | Tivdak, Epkinly |
| Ipsen Biopharmaceuticals, INC | $105.40 | 2023-2025 | Onivyde, Somatuline Depot |
| Adc Therapeutics America, INC. | $98.77 | 2022-2025 | |
| Blueprint Medicines Corporation | $98.49 | 2022-2025 | Ayvakit |
| Caris Mpi, INC. | $96.35 | 2025 | Mi Cancer Seek |
| Boehringer Ingelheim Pharmaceuticals, INC. | $91.27 | 2019-2025 | Gilotrif |
| Gilead Sciences, INC. | $87.62 | 2021-2025 | Trodelvy |
| Pharmacosmos Therapeutics INC. | $84.67 | 2024-2025 | Monoferric |
| Beone Medicines USA, INC. | $82.88 | 2025 | Brukinsa, Tevimbra |
| Apellis Pharmaceuticals, INC. | $75.99 | 2023-2025 | Empaveli |
| Tempus Ai, INC | $70.34 | 2024-2025 | Xt Cdx |
| Aveo Pharmaceuticals, INC. | $67.77 | 2023-2025 | Fotivda |
| Glaxosmithkline, LLC. | $65.16 | 2023-2025 | Jemperli, Ojjaara |
| Amneal Pharmaceuticals LLC | $64.20 | 2023-2025 | Alymsys, Neupogen, Avastin |
| Pharmacyclics LLC, An Abbvie Company | $60.60 | 2019-2023 | Imbruvica |
| Janssen Pharmaceuticals, INC | $58.98 | 2019-2023 | Xarelto |
| Stemline Therapeutics INC. | $54.90 | 2023-2024 | Orserdu |
| Beigene USA, INC. | $54.35 | 2023-2024 | Brukinsa |
| Jazz Pharmaceuticals INC. | $52.78 | 2020-2024 | Zepzelca |
| Stryker Corporation | $51.50 | 2025 | Optablate |
| Array Biopharma INC | $49.95 | 2022-2025 | Braftovi, Mektovi, Xalkori |
| Kyowa Kirin, INC. | $49.25 | 2023-2025 | Poteligeo |
| Deciphera Pharmaceuticals INC. | $45.23 | 2025 | Qinlock, Romvimza |
| Agios Pharmaceuticals, INC. | $44.75 | 2024-2025 | Pyrukynd |
| Geron Corporation | $43.50 | 2025 | Rytelo |
| Servier Pharmaceuticals LLC | $42.39 | 2024-2025 | |
| Adaptive Biotechnologies Corporation | $42.38 | 2024-2025 | Clonoseq |
| Sobi, INC | $41.42 | 2024-2025 | |
| Secura Bio, INC. | $39.86 | 2024-2025 | Copiktra |
| Rigel Pharmaceuticals, INC. | $38.86 | 2024-2025 | Rezlidhia, Tavalisse, Tavalisse |
| Emmaus Medical, INC. | $38.76 | 2023 | Endari |
| Spectrum Pharmaceuticals INC. | $37.89 | 2023-2025 | Rolvedon |
| Sumitomo Pharma America, INC. | $36.80 | 2024-2025 | Orgovyx |
| Clovis Oncology, INC. | $34.36 | 2019 | |
| Taiho Oncology, INC. | $29.45 | 2019-2025 | |
| Coherus Oncology, INC. | $27.32 | 2023 | |
| Pharmaessentia USA Corporation | $24.94 | 2024 | Besremi |
| Organon LLC | $23.71 | 2024 | |
| Pharming Healthcare, INC. | $22.75 | 2024 | Ruconest |
| Tesaro, INC. | $21.34 | 2019 | |
| Springworks Therapeutics, INC. | $20.34 | 2024 | Ogsiveo |
| Mirati Therapeutics, INC. | $20.00 | 2023 | Krazati |
| Progenics Pharmaceuticals, INC. | $19.60 | 2023 | Pylarify |
| Medtronic, INC. | $18.99 | 2025 | Inceptiv |
| Csl Behring | $18.72 | 2019 | |
| Morphosys, US INC. | $16.94 | 2023 | Monjuvi |
| Dova Pharmaceuticals | $15.91 | 2019 | |
| Cti Biopharma Corp. | $15.41 | 2023 | Vonjo |
| Advanced Accelerator Applications | $15.35 | 2019 | |
| Helsinn Therapeutics (U.S.), INC. | $15.20 | 2019 | |
| Tolmar, INC. | $14.80 | 2025 | Rubraca, Eligard |
| Pharmaand Gmbh | $14.80 | 2025 | Rubraca |
| Kite Pharma, INC. | $14.53 | 2025 | Yescarta |
| Novo Nordisk INC | $14.39 | 2023 | Rebinyn, Novoseven, Novoeight |
| Medtronic USA, INC. | $13.58 | 2019 |
Drugs and devices associated with these payments
Yonsa $4,444Libtayo $306Sir-Spheres Microspheres $268Venclexta $258Myrisk $227Imbruvica $217Lenvima $205Keytruda $203Imfinzi $196Reblozyl $178Enhertu $175Opdivo $171Epkinly $166Eliquis $149Verzenio $148Jaypirca $148Kisqali $137Fruzaqla $129Ibrance $121Tecvayli $114Xpovio $114Rybrevant $111Jakafi $111Brukinsa $110Onivyde $105Tukysa $105Lynparza $97.46Mi Cancer Seek $96.35Padcev $96.31Talvey $93.27Monoferric $84.67Paxlovid $83.77Monjuvi $81.33Ayvakit $77.31Empaveli $75.99Stivarga $71.24Calquence $68.85Somatuline Depot $68.31Fotivda $67.77Cabometyx $67.35Opdualag $60.80Braftovi $59.92Mektovi $59.92Darzalex $58.30Orserdu $54.90Orgovyx $54.15Pluvicto $53.79Fabhalta $53.67Vitrakvi $52.36Optablate $51.50Phesgo $50.29Tecentriq $50.08Scemblix $50.05Poteligeo $49.25Alymsys $47.99Ninlaro $46.70Xtandi $46.25Qinlock $45.23Carvykti $44.82Pyrukynd $44.75Tivdak $44.61Jemperli $43.83Rytelo $43.50Piqray $43.44Clonoseq $42.38Retevmo $42.33Comirnaty $42.08Alunbrig $41.60Zynlonta $40.93Xt Cdx $40.39Trodelvy $40.18Itovebi $40.07Copiktra $39.86Elrexfio $39.37Adcetris $39.37Rezlidhia $38.86Tavalisse $38.86Elahere $38.76Endari $38.76Rolvedon $37.89Altuviiio $36.82Nubeqa $35.78Lynozyfic $35.69Gilotrif $35.31Vonjo $34.90Inlyta $34.79Zepzelca $34.79Bosulif $32.38Talzenna $31.34Pomalyst $31.22Vyloy $31.19Sarclisa $31.08Rubraca $29.60Udenyca $27.32Tevimbra $27.12Polivy $25.76Lunsumio $25.76Niktimvo $25.58Besremi $24.94Tabrecta $24.83
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jay Sidloski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.